How big is BIOLASE, Inc.?

As of Jun 18, BIOLASE, Inc. has a market capitalization of 0.41 million, with net sales of 46.02 million and a net profit of -16.05 million over the last four quarters. The company reported shareholder's funds of -0.25 million and total assets of 35.10 million as of Dec 23.

Market Cap: As of Jun 18, BIOLASE, Inc. has a market capitalization of 0.41 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, BIOLASE, Inc. reported net sales of 46.02 million and a net profit of -16.05 million.<BR><BR>Balance Sheet Snapshot: As of Dec 23, the company reported shareholder's funds of -0.25 million and total assets of 35.10 million.

What does BIOLASE, Inc. do?

BIOLASE, Inc. is a medical device company specializing in laser systems for dentistry and medicine, with a market cap of $0.41 million and quarterly net sales of $11 million as of September 2024. The company is currently operating at a net loss of $1 million.

Overview: <BR>BIOLASE, Inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 11 Million (Quarterly Results - Sep 2024) <BR>Net Profit: -1 Million (Quarterly Results - Sep 2024) <BR>Market cap: USD 0.41 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.64 <BR>Return on Equity: 308.80% <BR>Price to Book: -0.08<BR><BR>Contact Details: <BR>Address: 4 CROMWELL, IRVINE CA: 92618-1816 <BR>Tel: 1 949 3611200 <BR>Fax: 1 949 2736677 <BR>Website: https://www.biolase.com/

Should I buy, sell or hold BIOLASE, Inc.?

Who are in the management team of BIOLASE, Inc.?

As of March 2022, the management team of BIOLASE, Inc. includes Dr. Jonathan Lord (Independent Chairman), Mr. Todd Norbe (President and CEO), and several Independent Directors: Dr. Michael DiTolla, Dr. Richard Lanman, Mr. Jess Roper, Mr. Garrett Sato, and Dr. Elaine Wagner.

As of March 2022, the management team of BIOLASE, Inc. includes the following individuals:<BR><BR>- Dr. Jonathan Lord, who serves as the Independent Chairman of the Board.<BR>- Mr. Todd Norbe, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Michael DiTolla, who is an Independent Director.<BR>- Dr. Richard Lanman, who is also an Independent Director.<BR>- Mr. Jess Roper, another Independent Director.<BR>- Mr. Garrett Sato, who serves as an Independent Director.<BR>- Dr. Elaine Wagner, who is also an Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors.

Is BIOLASE, Inc. technically bullish or bearish?

As of June 27, 2025, BIOLASE, Inc. shows a mildly bearish technical trend with weak performance, having a year-to-date return of -91.67% compared to the S&P 500's 12.22%.

As of 27 June 2025, the technical trend for BIOLASE, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are mildly bearish, and the weekly KST is bearish, which suggests underlying weakness. The Bollinger Bands show a mildly bearish stance on the weekly timeframe. Overall, the lack of strong bullish signals and the presence of bearish indicators lead to a mildly bearish technical stance.<BR><BR>In terms of performance, BIOLASE has significantly underperformed compared to the S&P 500, with a year-to-date return of -91.67% versus the S&P 500's 12.22%, and a one-year return of -98.2% compared to the S&P 500's 17.14%.